Our funders

NC3Rs funders 

In financial year 2023/24 the NC3Rs had a budget of £10.65M. We receive core funding from the MRC and BBSRC, which are part of UK Research and Innovation (UKRI). Core funding is reviewed every five years. In financial year 2023/24 the core funding allocation was £10M. In addition to this, we received funding for specific programmes and posts and co-funding for grants from other research funders. This included funding from the following organisations:

• Association of the British Pharmaceutical Industry (ABPI)* 
• British Heart Foundation 
• Cancer Research UK**
• Engineering and Physical Sciences Research Council**
• GSK 
• Shell 
• Syngenta 
• Corteva Agriscience 
• Unilever
• Wellcome 
• Bill and Melinda Gates Foundation 
• University of Oxford 
• Great Western 4 Alliance (University of Bath, University of Bristol, Cardiff University and University of Exeter)

* In accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Charles River Laboratories and UCB Pharma. 

** Payment made in advance and deferred to follow grant payment profiles.

Budget 

Table 1 shows the NC3Rs income and expenditure for the financial year 2023/24 Expenditure is divided across three areas – research and innovation awards made to universities and SMEs, support for early career researchers (e.g. funding for PhD studentships) and programmes led by NC3Rs scientific staff. There was an underspend of £160k due to unavoidable delays affecting scheduled payments in a small number of projects.

Table 1: Income and expenditure